Oceania: Food, Drugs, Healthcare, Life Sciences

A case on appeal in NSW focused on whether a sentence handed down for drug supply charges was excessive.

Synergistic combinations in patent law present unique challenges for inventors in chemical, pharmaceutical, and life sciences fields. While combining known components is common practice, only those combinations producing effects greater than the sum of their parts can constitute patentable inventions. This article explores the legal requirements, evidentiary standards, and practical strategies for successfully claiming synergistic effects under Australian patent law.

Australia's pharmaceutical patent landscape has reached a critical juncture, with appellate courts reconsidering fundamental principles of patent scope, term extensions, and remedies that will shape originator-generic disputes for the foreseeable future. As the High Court prepares to rule on patent term extensions for formulation patents and new Federal Court practice directions take effect, the strategic calculus for both innovators and generic entrants is being fundamentally rewritten.

Ministerial Direction 105 allows the government to issue instructions to Home Affairs on how skilled visas should be prioritised, typically taking into account regional needs, sponsorship status and critical sectors.

When seeking legal advice for complaints or referrals, it is important for health practitioners to understand the scope of their Professional Indemnity Insurance (PII). PII generally covers legal defence costs, assistance during investigations, and any damages or penalties that fall within the policy terms. However, most insurance policies contain clauses that prohibit practitioners from admitting liability without the consent of the insurer.

In recent amendments to the National Health Act 1953 (Cth) (‘the Act’), the Secretary of the Department of Health and Aged Care (‘the Secretary’) now has a wider scope of power to cancel the approval of approved pharmacists.

Australian patent law requires every invention to qualify as a 'manner of manufacture' under the Statute of Monopolies, yet this centuries-old concept continues to evolve through landmark litigation. The recent Aristocrat v Commissioner of Patents case has reshaped how courts assess computer-implemented inventions, while decisions like D'Arcy v Myriad Genetics have clarified boundaries for biotechnology patents, creating critical implications for businesses evaluating IP portfolios and freedom to operate.

The inquest into the death of Baby R highlighted issues regarding medical advice given over the course of the pregnancy and medical decision-making provided by attending midwives during the homebirth.

Synergistic combinations in patent law present unique challenges for inventors in chemical, pharmaceutical, and life sciences fields. While combining known components is common practice, only those combinations producing effects greater than the sum of their parts can constitute patentable inventions. This article explores the legal requirements, evidentiary standards, and practical strategies for successfully claiming synergistic effects under Australian patent law.